Evidence map›Paper›PMID 36619586›Full record

ReviewFrontiers in endocrinology2022

A rare pituitary tumor associated with hyperthyroidism and acromegaly.

Li Li, Liheng Meng, Yuping Liu, Rashi Tamrakar, Xi Yang, Xinghuang Liang, Jia Zhou, Jing Xian, Zhenxing Huang, Yingfen Qin

Abstract readCase ReportsReview
In one paragraph

Review in Frontiers in endocrinology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Li LiDepartment of Endocrinology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Liheng MengDepartment of Endocrinology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Yuping LiuDepartment of Endocrinology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Rashi TamrakarDepartment of Endocrinology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Xi YangDepartment of Endocrinology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Xinghuang LiangDepartment of Endocrinology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Jia ZhouDepartment of Endocrinology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Jing XianDepartment of Endocrinology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Zhenxing HuangDepartment of Endocrinology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Yingfen QinDepartment of Endocrinology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Mixed pituitary TSH/GH adenomas are rare adenomas associated with acromegaly and/or thyrotoxicosis, with or without varying degrees of goiter. In this report, we show a case of pituitary adenoma producing both GH and TSH simultaneously. Case presentation: A 27-year-old man was diagnosed with pituitary adenoma based on various symptoms and clinical findings. For further examination and treatment, he was hospitalized in our institution. It was likely that this subject had pituitary adenoma producing both GH and TSH. In brain magnetic resonance imaging, there was a giant tumor in the sellar region. After the diagnosis of mixed pituitary TSH/GH adenoma, he was treated with octreotide, then underwent tumor resection, and then received hydrocortisone acetate and levothyroxine sodium. After then, GH and IGF-1 levels were suppressed and thyroid function was normalized. Postoperative immunohistochemistry reports showed GH (+) but TSH (-), which may be insensitive to the antibody used to detect TSH or combined with other factors. Conclusions: The diagnosis of mixed pituitary TSH/GH adenoma must be combined with clinical manifestations, immunohistochemical staining and relevant hormone levels, and genetic testing if necessary for comprehensive judgment. For patients with large adenomas, it is recommended to use somatostatin analogs to restore TH levels and control the excessive secretion of GH levels before surgery.

Indexed as

AcromegalyAdenomaHyperthyroidismPituitary NeoplasmsAdultHumansMaleThyrotropinThyrotropingrowth hormoneimmunostainingmixed pituitary adenomarare diseasethyroid stimulating hormone

Identifiers

PMID36619586
PMCPMC9816123

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.